

## Bod Science Limited receives \$1.645 million R&D Tax Rebate

- \$1.645 million Research and Development (R&D) Tax Incentive Rebate received for 2023 financial year
- Funds received reflective of Bod's commitment and investment in Research and Development (R&D) on key projects over the last 12 months
- R&D Tax Rebate covers in full the loan repayable to Radium Capital of \$1.216 million

**Sydney, Australia – 22 November 2023:** Cannabis focused drug development and product innovation company Bod Science Limited ("**Bod**" or "**the Company**") (ASX: BOD) is pleased to advise that a \$1.646 million Research and Development (R&D) Tax Incentive Rebate for the 2023 financial year has been received. The R&D rebate covers in full the outstanding loan repayable to Radium Capital, which totals \$1.216 million, with the balance of \$0.43 million transferred to Bod.

The rebate relates to applicable R&D activities conducted by Bod during the 2023 financial year.

The rebate underscores Bod's commitment to drug development and product innovation including its ongoing clinical trial of a unique Schedule 3 (Pharmacist Only) CBD medicine which Bod has exclusively licensed under a five-year supply agreement to Australia's largest generic pharmaceutical and private label OTC medicines company, Arrotex Pharmaceuticals.

### Management commentary:

**CEO Ms Jo Patterson said:** *The R&D tax rebate highlights Bod's commitment over the last 12 months to our R&D projects specifically on our Schedule 3 OTC Phase IIB and our R&D work with Aqua Phase to support its commercialisation".*

**This announcement has been approved by the Chairman of Bod Science Limited.**

**-ENDS-**

### About Bod Science:

Bod Science (ASX: BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
Info@bodaustralia.com  
+61 2 9199 5018

Amalie Schreurs  
White Noise Communications  
amalie@whitenoisecomms.com  
+61 431 636 033